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Abstract

Chronic cannabis use has been associated with neurocognitive deficits, alterations in brain structure and
function, and with psychosis. This study investigated the effects of chronic cannabis use on P50 sensory-gating
in regular users, and explored the association between sensory gating, cannabis use history and the
development of psychotic-like symptoms. Twenty controls and 21 regular cannabis users completed a P50
paired-click (S1 and S2) paradigm with an inter-pair interval of 9. s. The groups were compared on P50
amplitude to S1 and S2, P50 ratio (S2/S1) and P50 difference score (S1-S2). While cannabis users overall did
not differ from controls on P50 measures, prolonged duration of regular use was associated with greater
impairment in sensory gating as indexed by both P50 ratio and difference scores (including after controlling
for tobacco use). Long-term cannabis users were found to have worse sensory gating ratios and difference
scores compared to short-term users and controls. P50 metrics did not correlate significantly with any
measure of psychotic-like symptoms in cannabis users. These results suggest that prolonged exposure to
cannabis results in impaired P50 sensory-gating in long-term cannabis users. While it is possible that these
deficits may have pre-dated cannabis use and reflect a vulnerability to cannabis use, their association with
increasing years of cannabis use suggests that this is not the case. Impaired P50 sensory-gating ratios have also
been reported in patients with schizophrenia and may indicate a similar underlying pathology.
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Abstract
Chronic cannabis use has been associated with neurocognitive deficits, alterations in brain structure
and function, and with psychosis. This study investigated the effects of chronic cannabis use on P50 sensorygating in regular users, and explored the association between sensory gating, cannabis use history and the
development of psychotic-like symptoms. Twenty controls and 21 regular cannabis users completed a P50
paired-click (S1 and S2) paradigm with an inter-pair interval of 9 seconds. The groups were compared on
P50 amplitude to S1 and S2, P50 ratio (S2/S1) and P50 difference score (S1-S2). While cannabis users
overall did not differ from controls on P50 measures, prolonged duration of regular use was associated with
greater impairment in sensory gating as indexed by both P50 ratio and difference scores (including after
controlling for tobacco use). Long-term cannabis users were found to have worse sensory gating ratios and
difference scores compared to short-term users and controls. P50 metrics did not correlate significantly with
any measure of psychotic-like symptoms in cannabis users. These results suggest that prolonged exposure to
cannabis results in impaired P50 sensory-gating in long-term cannabis users. While it is possible that these
deficits may have pre-dated cannabis use and reflect a vulnerability to cannabis use, their association with
increasing years of cannabis use suggests that this is not the case. Impaired P50 sensory-gating ratios have
also been reported in patients with schizophrenia and may indicate a similar underlying pathology.

Key words: Cannabis, P50, sensory gating, schizophrenia, event-related potentials

Chronic effects of cannabis on sensory gating

3

1.0 Introduction
Cannabis sativa is the most commonly used illicit substance in the world. Regular and prolonged
exposure to cannabis is associated with impaired cognition, particularly deficits in attention, learning and
memory (Solowij and Michie, 2007; Solowij and Pesa, 2010), alterations in brain structure and function
(Solowij et al., 2011; Yücel et al., 2008a; Yücel et al., 2008b), and deficits in electrophysiological indices of
pre-attentive processes (e.g. P50: Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick
and Struve, 2000; Rentzsch et al., 2007; and mismatch negativity, MMN: Greenwood et al., in revision;
Rentzsch et al., 2011; Roser et al., 2010) as well as selective attention (e.g. processing negativity and P300:
Solowij et al., 1995). Chronic cannabis use has also been shown to increase the risk of developing psychotic
symptoms in a dose-response fashion (Semple et al., 2005), and is considered by some to be a component
9

cause of schizophrenia in vulnerable individuals (D'Souza et al., 2009; Murray et al., 2007). Δ Tetrahydrocannabinol (THC) is the primary psychoactive constituent of cannabis and is linked with altered
cognition and the induction of psychotic-like symptoms (D'Souza et al., 2009). The subjective, behavioural and
cognitive effects produced by THC are most likely due to the action of THC as a partial agonist at central
cannabinoid (e.g. CB1) receptor sites (Pertwee, 2008), altering the regulatory action of the endocannabinoid
system on synaptic transmission and other neurotransmitter signalling, such as gamma-aminobutyric acid
(GABA), glutamate and dopamine (Lopez-Moreno et al., 2008; Mathur and Lovinger, 2012). CB1 receptors
occur in high density throughout the brain, particularly in the hippocampus, anterior cingulate, basal ganglia
and the cerebellum; regions which are involved in cognition and are particularly important for attention,
learning and memory (Bhattacharyya et al., 2009; Bossong and Niesink, 2010; Iversen, 2004). Impaired
cognition in chronic cannabis users is thought to be underpinned at least in part, by alterations to the
regulatory role of the endocannabinoid system on synaptic plasticity following prolonged and regular exposure
to exogenous cannabinoids such as THC (Hampson et al., 2011; Heifets and Castillo, 2009; Hoffman et al.,
2007; Puighermanal et al., 2012). In light of deficits in cognition (e.g., selective attention, verbal learning and
inhibition, Solowij and Michie, 2007), and alterations in brain function (e.g., prefrontal cortical, cingular,
hippocampal and cerebellar activation in imaging studies, Solowij and Michie, 2007; Martin-Santos et al.,
2010) and structure (e.g., reduced hippocampal volume, Yücel et al., 2008b) in long-term cannabis users
being similar to those observed in patients with schizophrenia, further investigation of neurobiological markers
of pre-attentive processes may inform mechanisms by which cannabis might result in schizophrenia-like
conditions in the brain and induce psychosis in vulnerable individuals.
Sensory gating is the brain’s ability to modulate its sensitivity to incoming stimuli (Braff & Geyer, 1990)
and includes its ability to inhibit response to irrelevant sensory stimuli and thus ‘gate-out’ repetitive and
redundant sensory stimulation of the brain (Boutros & Belger, 1999; Boutros et al., 1991; Brenner et al., 2009;
Freedman et al., 1983; Gjini et al., 2010; Hu et al., 2012). In contrast, ‘gating in’ is conceptualised as the
brain’s preattentive ability to identify significant stimulus change or novel sensory input (Boutros & Belger,
1999; Gjini et al., 2010). The P50 component is a positive event-related potential (ERP) marker of sensory
1

‘gating-out’ with a vertex maximum elicited approximately 50 milliseconds following an auditory stimulus. The
1

In this study, we focus specifically on P50 as a measure of sensory ‘gating-out’ (as defined by Boutros & Belger, 1999; Gjini et al., 2010)
and do not include a measure of ‘gating-in’ (e.g. mismatch negativity; see Gjini et al., 2010). While we henceforth refer to ‘P50 sensory
gating’, we implicitly mean ‘gating-out’ rather than ‘gating-in’.
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P50 component is typically investigated using an auditory paired-click paradigm in which pairs of brief
(approximately 1 millisecond) clicks are presented 500 milliseconds apart. In this paradigm, the amplitude of
the P50 component elicited to the second click is attenuated relative to the first click in healthy individuals.
The relative reduction in P50 amplitude to the second click within the pair (i.e. the ratio P50 to the second click
/ P50 to the first click) is the most commonly used marker of sensory gating in this context (Clementz et al.,
1997). Although the neural generators of the auditory P50 evoked potential have been localised to Heschl’s
gyrus (Knott et al., 2009; Korzyukov et al., 2007; Weisser et al., 2001), the neurobiological underpinnings
associated with the phenomenon of sensory gating are less clear (Korzyukov et al., 2007). While it is possible
that the populations of neurons in the auditory cortex activated to the first click undergo a refractory period
and therefore cease to be active to the second click, there is increasing evidence to suggest that additional
inhibitory inputs attenuate the brain’s response to repetitive stimuli and specifically the P50 response to the
second click (see, Korzyukov et al., 2007). Evidence from animal work suggests these inhibitory inputs may
arise in the CA3 region of the hippocampus and are involved in sensory gating (Freedman et al., 1996). In
humans however, intracranial recordings have revealed that hippocampal engagement occurs approximately
200 milliseconds post-stimulus and therefore, although not directly related to P50 generation (Grunwald et al.,
2003), instead may suppress P50 generators activated by the second click (Korzyukov et al., 2007). Also
implicated in sensory gating are generators in the frontal lobe (Korzyukov et al., 2007; Weisser et al., 2001),
superior temporal gyrus (Thoma et al., 2005), prefrontal cortex (Grunwald et al., 2003), and cingulate and
parietal lobe regions (Boutros et al., 2013), along with multiple neurotransmitter systems including GABAergic,
cholinergic, dopaminergic, serotonergic and glutamatergic systems (Adler et al., 1998). Relevant to the
current study and as noted earlier, THC is thought to disrupt the regulatory action of the endocannabinoid
system on these neurotransmitter systems (Lopez-Moreno et al., 2008; Mathur and Lovinger, 2012).
Impaired P50 suppression has been reported extensively in patients with schizophrenia (Bramon et
al., 2004), and is a candidate endophenotype for the disorder (Braff and Light, 2005) with P50 deficits
observed at an intermediate level in unaffected family members of patients with schizophrenia (e.g., Clementz
et al., 1998b) and associated with schizotypy in a non-clinical population (Croft et al., 2001). Meta-analyses
suggest P50 ratios in patients with schizophrenia are 1.28 to 1.56 standard deviations larger than those of
healthy controls, although there is large variability in P50 ratios between studies (Bramon et al., 2004; de
Wilde et al., 2007). Despite the relatively robust finding of altered sensory gating, the association between
symptomatology and P50 suppression in patients with schizophrenia is less clear. Croft et al., (2004) argue
this may be a function of medication status or lifestyle factors such as smoking history. Pharmacological work
has highlighted the involvement of the α-7 nicotinic receptor in P50 sensory gating (Hajos and Rogers, 2010),
compatible with improved P50 suppression in cigarette smokers (Crawford et al., 2002) and underlining the
potential for tobacco use to confound P50 measurement in patient studies given the increased rates of
smoking in this group (Croft et al., 2004). There is also large variability in P50 measures across studies,
including the measurement of P50 amplitude (peak to peak vs. baseline to peak), the number of trials
contributing to an average, time on task and the time between click pairs (inter-pair interval, Dalecki et al.,
2011).
A small body of research has examined P50 sensory gating in cannabis users. This work has
reported reduced P50 suppression in chronic cannabis users compared to non-user controls (Edwards et al.,

Chronic effects of cannabis on sensory gating

5

2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick and Struve, 2000; Rentzsch et al., 2007), and
interestingly in comparison to patients with schizophrenia with and without concurrent cannabis use (Rentzsch
et al., 2007). Some of these studies found that poor sensory gating in cannabis users is associated with
prolonged durations of exposure (Rentzsch et al., 2007) and dose (the number of joints smoked in the
previous six months, Edwards et al., 2009). The association between P50 sensory gating and propensity to
develop psychotic-like symptoms associated with prolonged exposure to cannabis has not been addressed in
prior work. Nor have the above studies attempted to control for patterns of tobacco use, which may affect
these data given the high rates of tobacco use by cannabis users. The current study attempted to explore
both of these issues and to clarify the association between prolonged exposure to cannabis and sensory
gating more precisely. Further, consistent with prior work demonstrating impairments in verbal learning in
cannabis users and patients with schizophrenia (Solowij and Michie, 2007), we explored a potential
association between a measure of verbal learning and P50 sensory gating. Finally, prior research in cannabis
users focused predominately on a ratio measure of sensory gating (Edwards et al., 2009; Patrick et al., 1999;
Patrick and Struve, 2002; Patrick and Struve, 2000; Rentzsch et al., 2007), while more recent research also
investigated the difference metric (P50 amplitude to S1 – P50 amplitude to S2) with mixed results (Edwards et
al., 2009; Rentzsch et al., 2007). In accordance with this recent work and research which suggests that the
P50 difference score may be a more reliable index of sensory gating (Smith et al., 1994), the current study
compared cannabis users with controls on both P50 ratio and difference measures (see also Chang et al.,
2011 for a meta-analysis of S1, S2 and P50 ratio differences in patients with schizophrenia and controls).
First, we set out to replicate the findings of reduced P50 suppression in chronic cannabis users by comparing
P50 metrics in regular cannabis users and age- and gender-matched healthy non-user controls. Consistent
with prior work, we predicted that in comparison to non-user controls, chronic cannabis users would exhibit
significantly larger P50 ratios, and smaller P50 difference scores, indicative of impaired sensory gating.
Second, we explored the association between the degree and duration of cannabis exposure, and of
psychotic-like symptoms, verbal learning and P50 sensory gating.

2.0 Materials and Method
2.1 Participants
Twenty-one regular cannabis users and twenty-one non-user controls took part in the study.
Participants were recruited via an advertisement in a local newspaper and were first screened over the
telephone to ensure they met inclusion criteria. Regular cannabis use was defined as minimum fortnightly use
for at least two years. Control participants were required not to have used cannabis more than 20 times in
their life and not at all in the previous year. Exclusion criteria included regular polysubstance use within the
previous two years, or use of an illicit substance within the past month (other than cannabis for the cannabis
group), a current psychiatric diagnosis, and a neurological or medical disease that would interfere with EEG
testing. Participants were asked to abstain from using cannabis, alcohol or any illicit substance for a minimum
of 12 hours prior to testing, and self-reported cannabis use and abstinence from other drugs was corroborated
by urinalysis. Participants also abstained from cigarettes and caffeinated drinks during testing: EEG protocols
were completed 1.5 hours into the testing schedule. To screen for the presence of a psychiatric condition the
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Kessler Psychological Distress Scale (K10, Andrews and Slade, 2001) was administered over the phone to all
participants. Participants were also asked detailed questions about whether they had ever been diagnosed
with any psychological/psychiatric disorders as part of a structured interview administered during the testing
session. One control participant was excluded after they admitted to currently taking an anti-epileptic
medication. Two participants in the cannabis user group reported that they had used ecstasy on a single
occasion between 2 and 4 weeks prior to testing. No amphetamine derivatives were detected in their urines
and therefore data from these participants were included in the analysis. No polysubstance use was reported
in the non-user control group, and was minimal in the cannabis user group: 2 participants reported regular
cocaine use over 15 years ago, and two other participants reported a period of regular (approximately 6
months) amphetamine use over 2 years ago. The study was approved by the University of Wollongong and
Illawarra Shoalhaven Local Health District Health and Medical Human Research Ethics Committee.
2.2 Procedure
All participants were familiarised with the study procedure before written informed consent was
obtained. Demographic and detailed substance use information was then obtained through a structured
interview, and alcohol consumption was assessed using the Alcohol Use Disorder Identification Test (AUDIT,
Saunders et al., 1993). Full scale IQ was estimated using the vocabulary and matrices subscales of the
Wechsler Abbreviated Scale of Intelligence (WASI, Wechsler, 1999). All participants were asked to complete
the Community Assessment of Psychic Experiences (CAPE, Stefanis et al., 2002) and Schizotypal Personality
Questionnaire (SPQ, Raine, 1991) as measures of psychotic-like symptoms, and cannabis users also
completed the Cannabis Experiences Questionnaire (CEQ, Barkus et al., 2006) as a measure of symptoms
experienced while intoxicated, the Marijuana Withdrawal Checklist (MWC, Budney et al., 2004) and the
Severity of Dependence Scale (SDS, Gossop et al., 2002). The Rey Auditory Verbal Learning Task (RAVLT)
was also administered to all participants. Handedness was assessed using the Edinburgh Handedness
Inventory (Oldfield, 1971) and all participants underwent audiometric testing to screen for hearing
impairments; all were found to have hearing within the normal range (i.e. ≤ 25 dB) at 1000Hz and 1500Hz.
EEG electrodes were then fitted, and participants first completed an eye-movement calibration task (Croft and
Barry, 2000) and multi-feature mismatch negativity paradigm (Greenwood et al., in revision; Todd et al., 2008)
before completing the P50 paired-click paradigm. All participants were reimbursed AUD$50 for their
participation.
2.3 Experimental paradigm
The P50 task comprised one 10-minute block of 100 pairs of click stimuli. To control attention,
participants were instructed to silently count each of the pairs of clicks and respond with a button press after
th

every 25 click pair. Prior research suggests there are no differences between ‘active’ paradigms which
control attention by counting or button pressing, and passive paired click paradigms on P50 metrics (Jerger et
al., 1992; Kho et al., 2003; White & Yee, 1997). Participants were asked to minimise movement and to keep
their eyes open, resting their gaze on the computer monitor in front of them. The stimuli were auditory clicks of
1 ms duration and presented binaurally using headphones (Sennheiser HD215) at 90 dB SPL. The first and
second clicks within a pair were separated by a fixed inter-stimulus interval of 500 ms. The inter-pair interval
(IPI) was the duration between the second click within a click pair and the first click of the next pair. There
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were two different IPI conditions, a long IPI condition in which click pairs were presented with an average of 9
seconds apart (in order to give the appearance of randomness, 3 different IPIs were chosen for each
condition, the mean of which was the target IPI: e.g. 8930, 8990 or 9080ms) and a short IPI condition in
which click pairs were presented an average of 3 seconds apart. The current study will focus on data from the
9 second IPI condition as this condition is most comparable to paired-click paradigms employed in previous
research (e.g., Edwards et al., 2009; Patrick et al., 1999; Patrick and Struve, 2002; Patrick and Struve, 2000;
Rentzsch et al., 2007). Data for the 3 second IPI condition were collected as part of another study and will not
be discussed further here. Fifty pairs of each of the short and long IPI conditions were presented in a random
fashion.
2.4 Electrophysiological data acquisition
Electroencephalographic (EEG) data were recorded continuously from 19 Ag/AgCl electrodes
positioned on an Electrocap according to the international 10-20 system (FP1, FP2, F3, Fz, F4, F7, F8, C3,
Cz, C4, P3, Pz, P4, T3, T4, T5, T6, O1 and O2), and two electrodes positioned over the left and right mastoid.
EEG data were grounded to an electrode placed midway between FPz and Fz, and referenced online to an
electrode positioned on the tip of the nose. Four monopolar electrodes were placed above and below the left
eye and 1 cm from outer canthi of the left and right eye and used to calculate vertical, horizontal and radial
electrooculogram (EOG) data required for the EOG correction procedure of Croft and Barry (2000). Data were
sampled at 500 Hz, with a bandpass filter of 0.1 to 100 Hz. All electrode impedances were below 10 kΩ at the
start of recording.
2.5 Electrophysiological data analysis
EEG data were analysed offline using Neuroscan software (Scan 4.4). Data were re-referenced
offline to the average of the mastoids and corrected for ocular artifacts according to Croft and Barry (2000).
Data were bandpass filtered from 10 to 45 Hz (down 12 dB/octave roll off), epoched from 100 ms pre-stimulus
to 300 ms post-stimulus, and baseline corrected using the 100 ms pre-stimulus interval. Epochs were
rejected if signals at any EEG channel exceeded ± 50 µV. EEG epochs were then averaged to the first (S1)
and second (S2) click.
P50 peaks were identified as the largest positive peak ± 15 ms around the peak of the average P50
peak latency in the grand mean (i.e. 62 ms ± 15 ms) following the Na peak (i.e. 48 ± 15 ms) and were
required to have a frontocentral topography (Rentzsch et al., 2007). No minimum peak amplitude was
required for a peak to be classified as such. An automatic peak detection algorithm was applied first and the
data were then verified visually by an experienced researcher, although not blind to group status. If no peak
was present within the specified latency range and/or did not have a frontocentral topography, the P50
amplitude was scored as ‘0’ (see also Dalecki et al., 2011). P50 data were measured at Cz only, in
accordance with Clementz et al., (1998a), relative to the peak of the preceding peak (Na). The following P50
measures were computed: P50 peak to peak amplitude to the first (S1) and second (S2) click; P50 ratio,
defined as the ratio of P50 peak amplitudes (i.e. S2/S1, where smaller P50 ratios are indicative of better
sensory gating); and P50 difference, defined as the difference between P50 peak amplitude to the first and
second click (i.e. S1- S2, where larger difference scores are indicative of better sensory gating).
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2.6 Statistical analysis
The groups were compared on demographic variables and measures of psychotic-like symptoms
using independent samples t-tests (or Mann-Whitney U tests where data were not normally distributed). P50
measures were not consistently normally distributed in the chronic cannabis user group, so all data were
transformed using a square root transformation to approximate normality. Univariate ANOVAs were then used
to examine the effect of Group (cannabis, control) on each transformed P50 variable (P50 amplitude to the
first (S1) and second (S2) click stimuli, P50 ratio and P50 difference). Pearson’s correlations were used to
examine the association between transformed P50 measures and cannabis use measures (also transformed
using a natural log transformation, and including duration of regular (weekly and daily) cannabis use,
frequency and quantity of use, age at which participants first tried cannabis, age of onset of regular use,
number of hours since participants last smoked cannabis, and urinary cannabinoid metabolite levels (THCCOOH, creatinine normalised)). Given the previously reported association between P50 gating, nicotine
exposure and α-7 nicotinic receptor activity, we re-ran the aforementioned correlations using Pearson’s partial
correlations controlling for tobacco use defined as the number of cigarettes smoked per day. To further
examine the effect of prolonged exposure to cannabis on P50, the cannabis group was divided into short- and
long-term users using a median split procedure. Univariate ANOVAs compared P50 amplitude to S1 and S2,
P50 ratio and P50 difference scores in short- and long-term users with non-user controls and with each other.
Finally, a natural log transformation was applied to the following variables: CAPE total frequency score, CAPE
total distress score, SPQ total score, CEQ Euphoric experiences score, CEQ Paranoid Dsyphoric score, CEQ
Amotivational score, CEQ After effects score and CEQ psychotic like experiences score. With the exception of
MWC score, RAVLT total score and SPQ total score, all other variables were successfully transformed.
Pearson’s correlations were used to explore the association between P50 ratio and difference score and
CAPE total frequency and distress scores as well as each CEQ subscale. Spearman’s correlations were used
to examine the association between the untransformed MWC score, RAVLT total score and SPQ total score
and P50 measures. P50 data (transformed) were examined for outliers (±1.5 times the inter-quartile range)
and analyses were repeated with and without identified outliers excluded. Where the pattern of effects
remained unchanged the data were retained in their original form and the analyses with all cases included are
reported. Where the pattern of results changed following the exclusion of outliers, the data are reported with
and without outliers included.

3.0 Results
3.1 Demographic, substance use and psychotic-like symptoms
Demographic, substance use and psychotic-like symptom measures for cannabis users and controls
are provided in Table 1. Cannabis users did not differ significantly from controls in terms of age or gender. All
participants were right-handed. Cannabis users had used cannabis regularly for a median 9.4 years (range
2.6 to 36.0 years), at a rate of approximately 4 joints per day on a median of 27 days per month (range 15 to
30 days/month). Cannabis users had significantly fewer years of education, lower IQ scores and recalled
significantly fewer words than controls on the RAVLT. Cannabis users consumed a greater quantity of alcohol
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and tended to drink more frequently than controls. However none of these variables were found to correlate
with P50 (S1 or S2 amplitudes, P50 ratio or P50 difference score; all p values > .10 for the control group, and
p > .29 for the cannabis group) and were therefore not appropriate for inclusion as covariates in subsequent
analyses. Cannabis users also smoked more cigarettes per day than controls, and although P50 metrics were
not associated with cigarettes per day in the cannabis group (p values > .80), given the aforementioned
association with P50 gating in the literature and an association between duration of cannabis use and
cigarettes smoked per day (r(21) = .59, p = .02) in the current dataset, we controlled for the possible effects of
tobacco use on P50 when testing for associations with cannabis use, using partial correlations. Finally,
although cannabis users tended to have higher CAPE total frequency scores compared to controls, the
groups did not differ in terms of total CAPE distress or SPQ scores.
3.2 Sensory gating in cannabis users and non-user controls
Grand mean ERP waveforms to the first (S1) and second (S2) click at Cz are presented for cannabis
users and controls in Figure 1 and mean (SD) P50 amplitude to S1 and S2, P50 ratio and difference score are
presented in Table 2. Cannabis users were not found to differ from controls in terms of P50 amplitude to S1
(F(1,39) = 0.99, p = .33), P50 amplitude to S2 (F(1,39) = 0.45, p = .51) or P50 difference score (F(1,39) =
2.57, p = .12). A main effect of group reached trend level for P50 ratio (F(1,39) = 3.44, p = .07) indicating
larger P50 ratios in cannabis users relative to controls. However, two outliers were identified in the control
group and when the analysis was repeated without these cases included, the effect of group was nonsignificant (F(1,37) = 1.15, p = .22). P50 ratio and difference scores were found to be significantly associated
with the overall duration of regular use (P50 ratio: r(21) = .44, p = .05, P50 difference: r(18) = -.49, p = .04;
see Figure 2) and P50 ratio tended to be associated with the duration of daily cannabis use (r(18) = .46, p =
.054) indicating larger P50 ratio and smaller P50 difference scores (worse sensory gating) with prolonged
exposure to cannabis. After controlling for cigarette use in partial correlations, the association between P50
ratio and duration of cannabis use was reduced to trend level (r(13) = .48, p = .07), while the association with
P50 difference score remained significant (r(13) = -.69, p = .01). Further, the association between P50 ratio
and duration of daily use was no longer significant after controlling for cigarette use (r(11) = .46, p = .12). No
association was identified for P50 ratio or difference score and any other measure of cannabis use (all p
values > .10; including after controlling for cigarette use). Finally, no associations between P50 ratio nor P50
difference score and time since last use (p values > .80), urinary cannabinoid metabolite levels (p values >
.10) or score on the MWC (p values > .10) were identified.
3.3 Sensory gating in long- versus short-term cannabis users
Grand mean ERP waveforms to the first (S1) and second (S2) click at Cz are presented for short- and
long-term cannabis users and controls in Figure 3 and mean (SD) P50 amplitude to S1 and S2, P50 ratio and
difference score are presented in Table 2. In terms of group characteristics, long-term cannabis users had
used cannabis regularly for a median of 23.2 years, and were currently using approximately 2 joints per day
for a median of 26 days per month. Short-term users had used cannabis regularly for a median duration of
6.1 years and used approximately 4 joints per day, on a median 29 days per month. Long-term users were
older than short-term users, had used cannabis regularly for longer and reported fewer withdrawal symptoms,
but did not differ in any other cannabis use parameters. Compared to controls, short-term users had
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significantly higher CAPE frequency scores and recalled significantly fewer words on the RAVLT. Age was not
found to be associated with any P50 measure for controls (p values > .10), short-term (p values > .10) or longterm cannabis use groups (p values > .19). Since age and duration of cannabis use were highly correlated
(rho = 0.734, p = .002), and age did not correlate significantly with any P50 measure for any group, age was
not considered appropriate for inclusion as a covariate.
Short-term cannabis users did not differ from controls in terms of any P50 measure (P50 S1: F(1,28)
= 0.06, p = .80; P50 S2: F(1,28) = .02, p = .90; P50 ratio: F(1,28) = 0.37, p = .55); P50 difference
score:F(1,28) = 0.21, p = .65). For the comparison of long-term users and controls, no effect of group was
observed for P50 amplitude to S1 (F(1,29) = 1.45, p = .24) or S2 (F(1,29) = 0.75, p = .39), however a
significant effect of group was observed for P50 ratio (F(1,29) = 5.64, p = .02) and P50 difference score
(F(1,29) = 4.35, p = .05), such that P50 ratios were increased and P50 difference scores decreased in longterm cannabis users.
Finally, for the comparison of long- and short-term users, no effect of group was identified for P50 to
S1 or S2, P50 ratio or difference score (P50 S1: F(1,19) = 1.50, p = .24; P50 S2: F(1,19) = 0.65, p = .43; P50
ratio: F(1,19) = 2.53, p = .13; P50 difference: F(1,19) = 2.21, p = .15). However for P50 amplitude to S1, one
outlier in the long-term group was identified, and for P50 ratio and difference score, 1 outlier was identified in
the short-term group. When the analysis was repeated with these outliers excluded, long-term users were
found to have significantly reduced P50 S1 amplitude, significantly larger P50 ratios and significantly smaller
difference scores than short-term users (P50 S1: F(1,18) = 5.64, p = .03; P50 ratio: F(1,18)=4.47, p = .05; P50
difference: F(1,18) = 5.06, p = .04). Furthermore, no association between P50 ratio or difference score, and
recency of cannabis use (time since last used and urinary cannabinoid metabolite levels) or withdrawal
measures (MWC score), was observed in either the long- or short-term user groups (all p values > .08).
3.4 Associations between P50 metrics, verbal learning and psychotic-like symptoms in
cannabis users
No association between our measure of verbal learning or any measure of psychotic-like symptoms
and P50 ratio or difference score was observed in the total sample of cannabis users, or in the short- or longterm user groups (all p values > .10).

4.0 Discussion
In this study we report an association between prolonged durations of exposure to cannabis and
larger impairment in sensory gating as indexed by P50 ratio and difference scores. Consistent with prior work,
long-term cannabis users were found to exhibit larger P50 ratios relative to controls, and we also found
evidence for reduced P50 difference scores. Previous studies of cannabis users that included P50 difference
scores reported mixed results: Edwards et al., (2009) found that only P50 ratio but not P50 difference scores
differentiated cannabis users from controls, while Rentzsch et al., (2007) reported significantly larger P50
ratios and P50 difference scores in cannabis users. The latter study, however, focused all subsequent
analyses on P50 ratio only and did not explore P50 difference scores further. Although the group difference
for P50 ratio in our overall sample of cannabis users and controls reached trend level only, we observed an
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association between duration of cannabis use and P50 metrics suggesting protracted exposure to cannabis
was associated with impaired sensory gating even after controlling for tobacco use. Rentzsch and colleagues
(2007) also reported an association between P50 gating and daily cannabis consumption, while Edwards et
al. (2009) found an association between gating and the quantity of cannabis used in the previous six months.
Neither study accounted for the possible effect of cigarette smoking on these measures. The current study
represents the first attempt to account for tobacco use when examining P50 metrics in cannabis users.
To explore the nature of the effect of duration of cannabis use on P50 further, we used a median split
to divide the sample of users into long- and short-term user groups, finding significantly larger P50 ratios and
reduced P50 difference scores (indicative of a gating deficit) in long-term users compared to non-user controls
and short-term users. Interestingly however, the short-term user group had a history of exposure to cannabis
that was more similar to the duration of use of the samples of cannabis users in the studies of Edwards et al.
(2009) and Rentzsch et al. (2007), with significantly fewer years of cannabis use than the median 23 years of
our long-term users. Nevertheless, the current pattern of findings highlights the importance of the duration of
exposure on sensory gating, and suggests the P50 difference score may be particularly sensitive to deficits in
long-term cannabis users. P50 difference scores are arguably a more psychometrically reliable method than
P50 ratio (Smith et al., 1994), however it is also possible that P50 ratio and difference scores may reflect
slightly different neurobiological processes (Smith et al., 1994) and this may in part account for the difference
in the pattern of results we report here as a function of cannabis use and prior research (e.g., Edwards et al.,
2009). Long-term users were also observed to have significantly smaller P50 amplitude to the first click, a
finding consistent with the patient literature (e.g. Clementz and Blumenfeld, 2001; Smith et al., 2010) and
suggests long-term exposure to cannabis may adversely affect encoding as well as well as gating (Smith et
al., 2010).
Consistent with prior work, cannabis users exhibited impaired verbal learning memory compared to
controls (Solowij and Michie, 2007), although no association with P50 measures was observed. We also set
out to explore a possible association between the presence of psychotic-like symptoms in cannabis users and
P50 sensory gating deficits as a potential marker of vulnerability to psychosis. Although prior work has found
an association between P50 ratio and schizotypy in non-clinical populations (Croft et al., 2004; Croft et al.,
2001), the current study did not observe any association between P50 metrics and psychotic-like symptoms in
long-or short-term cannabis users, including a retrospective measure of psychotic-like symptoms during
intoxication. This lack of association bears some similarity with the inconsistent relationship between
symptomatology and P50 deficits reported in patients with schizophrenia (Potter et al., 2006). Further, it
should be noted that only the short-term users in our sample differed significantly from controls in terms of one
measure of psychotic-like symptomatology (CAPE frequency scores), and this suggests that perhaps the
current sample of cannabis users were not particularly psychosis-prone (consistent with no clear differences
between controls and cannabis users on our two measures of psychotic-like experiences). Our study
exclusion criteria were strict with regard to psychiatric history, and it is plausible that our sample of cannabis
users were less susceptible to developing psychosis, particularly given that despite their prolonged histories of
exposure to cannabis, none had developed psychosis. It is also interesting however, that short-term users
reported a greater number of paranoid dysphoric and psychotic-like experiences during intoxication compared
to long-term users. One possibility is that given their younger age, short-term users may have been exposed
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to more potent (high THC content) forms of cannabis during a neurodevelopmentally critical period associated
with these increased psychotic-like experiences, although we did not observe a significant effect on P50
gating. This group difference should also be considered alongside demographic differences between shortand long-term groups including a greater proportion of males, younger age and lower IQ scores in the shortterm group which may also have influenced sensory gating effects and associations between P50 metrics and
psychotic-like experiences. Nevertheless, in light of increasing evidence of an association between cannabis
and psychosis, and the fact that P50 deficits are extensively reported in patients with schizophrenia, and
those at risk of developing the disorder (Bramon et al., 2004), our findings provide some support for the notion
that chronic cannabis use may result in an underlying pathology similar to schizophrenia (Solowij and Michie,
2007).
The mechanisms by which exogenous cannabinoids such as THC might affect P50 gating are largely
unknown, however consistent with rat models of sensory gating (Boutros et al., 1997; Boutros and Kwan,
1998; Dissanayake et al., 2013), as well as intracranial recordings in humans which have implicated
hippocampal involvement (e.g., Grunwald et al., 2003), disrupted sensory gating in cannabis users might be
due to the partial agonist effects of THC at CB1 receptors in the hippocampus in terms of reducing GABAergic
inhibition of excitatory glutamatergic neurons (Dissanayake et al., 2013). This could lead to deficits in
inhibitory processing, including reduced inhibitory inputs to P50 generators in auditory and frontal cortices.
Consistent with this notion, when CB1 agonists were administered to rats, sensory gating was disrupted as
measured by local field potentials in the CA3 region of the hippocampus (Dissanayake et al., 2008; Hajos et
al., 2008) as well as the medial prefrontal cortex (Dissanayake et al., 2008). Further work, however, is
required to elucidate the interaction between cannabis, the endogenous cannabinoid and other
neurotransmitter systems such as prefrontal dopamine circuits which have also been implicated in sensory
gating (for a review see, Gallinat et al., 2012). A related methodological issue is the use of an active paradigm
in order to control attention and the possibility of differential effects of attention as a function of group status
on sensory gating. To date, research examining the effects of cannabis on P50 has used both active attention
paradigms (e.g. Edwards et al., 2009) and passive tasks (e.g. Patrick et al., 1999; Rentzsch et al., 2007). Gjini
et al. (2011) found attention to S2 increased the S1 response in both healthy controls and patients with
schizophrenia, while only S2 amplitudes increased as a function of attention in healthy participants. This
resulted in improved sensory gating ratios in patients, and a reduced group difference (Gjini et al., 2011).
Future studies might consider using both passive and active paired click paradigms in order to ascertain
whether attention might have a differential effect on sensory gating in cannabis users.
There are a number of limitations in the current study that may be addressed in future work. First,
future research could extend these findings to a larger sample of cannabis users. Second, further
consideration of study inclusion/exclusion criteria regarding personal and familial psychiatric history to include
potentially more psychosis-prone individuals might address the efficacy of P50 deficits in cannabis users as a
possible marker of vulnerability to psychosis. For example, longitudinal work investigating P50 deficits and the
development of psychotic symptoms would serve to clarify the role of chronic cannabis exposure and
vulnerability to psychosis, and genetic moderation of effects might be examined. Third, it is possible that the
P50 deficits we observed in long-term users may have pre-existed cannabis use, although the association
with duration of use and impaired sensory gating ratios suggests this is unlikely. Nevertheless, longitudinal
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work would facilitate our understanding of premorbid functioning in cannabis users and help clarify the role of
prolonged exposure to cannabis on these measures. Fourth, although the current findings are most likely the
result of chronic cannabis use, there are alternative explanations including possible residual effects of THC
associated with recent use (Pope et al., 2001) or effects associated with withdrawal (Budney et al., 2004).
However these explanations are unlikely as we found no association between P50 measures and either
recency of cannabis use (time since last use or urinary cannabinoid metabolite levels) or withdrawal
measures. Participants in the current study were asked to abstain from using cannabis (alcohol or any other
illicit substance) for at least 12 hours prior to the experiment (median time since last use was 15 hours), so
they were not acutely intoxicated and withdrawal effects were minimal. Future work however could examine
the acute effects of cannabis on P50 metrics in regular and non-naive non-users to address these issues.
Finally, while we found age to not be correlated with P50 measures in any group in our sample (although see
Patterson et al. (2008) for a review of age effects on P50 gating in patients with schizophrenia), it is difficult to
disentangle the effects of age and duration of use (long-term cannabis users were older than short-term
users) on sensory gating. Future work should attempt to better match long- and short-term cannabis use
groups on demographic variables such as age to more fully understand and interpret these effects. Future
work might also examine the contribution of altered neural oscillations to sensory gating deficits in chronic
cannabis users (see also Edwards et al., 2009) as well as applying wider filter settings to examine the
potential role of lower frequency oscillations in P50 sensory gating (see Jansen et al., 2004).
In summary the findings from the current study suggest that regular, long-term exposure to cannabis
may be associated with impairments in auditory sensory gating as indexed by P50 metrics. P50 deficits are
also extensively reported in patients with schizophrenia and arguably represent a candidate endophenotype
for the disorder. In combination, mounting evidence of cognitive, electrophysiological, structural and functional
brain abnormalities observed in chronic cannabis users and patients with schizophrenia, along with the
current data suggest chronic cannabis use may result in schizophrenia-like conditions in the brain with
common underlying pathology (Solowij and Michie, 2007). Impairments in sensory gating processes as a
result of chronic exposure to cannabis may be related to disruption of the regulatory role of the
endocannabinoid system on synaptic neurotransmission, and particularly the disruption of CB1 receptor
activity in hippocampal and anterior cortical regions.
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Table(s)
Table 1. Demographic data, substance use measures and symptoms in cannabis user and healthy nonuser control groups. Median (range) are displayed.
Control (C)
n = 20

Cannabis (ALL)
n = 21

Short-term (S-T)
n = 10

Long-term (L-T)
n = 11

All v C

S-T v C

L-T v C

S-T v L-T

p

p

p

p

Age (years)

24.7 (18.1-52.6)

26.4 (18.5-52.0)

20.5 (18.5-26.4)

39.61 (21.4-52.0)

.696

.214

.072

.000

Gender (M/F)

8/12

14/7

8/2

6/5

.121

.058

.477

.361

112.5 (89-125)

104 (86-135)

94 (86-116)

109 (94-135)

.040

.000

.910

.005

14.3 (11.5-18.0)

12.0 (10.0-17.0)

12.1 (11.0-14.0)

12.0 (10.0-17.0)

.001

.000

.020

.666

RAVLT (Total 1 to 5)

56.5 (29.0-71.0)

45.0 (28.0-62.0)

42.5 (28.0-52.0)

49.0 (29.0-62.0)

.002

.000

.095

.223

Cigarettes per day

0 (0-11)

4 (0-20)

2.5 (0.0-12.5)

7.0 (0.0-20.0)

.000

.017

.000

.099

Alcohol frequency (days/month)

2.1 (0.0-4.0)

30.0 (0.0-30.0)

2.5 (0.0-10.0)

3.0 (0.0-30.0)

.099

.397

.079

.349

Alcohol quantity (drinks /month)

6.4 (0.0-70.0)

20.0 (0.0-180.0)

14.9 (0.0-96.0)

21.0 (0.0-180.0)

.049

.131

.095

.863

CAPE Frequency total

57 (45-89)

64 (50-90)

65 (52-92)

64 (42-84)

.099

.040

.471

.314

CAPE Distress total

17 (4-50)

32 (13-79)

36 (13-79)

27 (0-53)

.196

.069

.735

.223

SPQ total

12 (0-39)

27 (0-42)

33 (1-42)

21 (0-34)

.220

.157

.576

.128

a

IQ

Education (years)

a

Psychotic-like symptoms

CEQ Euphoric experiences

-

49 (29-72)

44 (35-56)

37 (29-72)

-

-

-

.105

CEQ Paranoid Dsyphoric

-

44 (25-76)

48 (33-76)

33 (25-56)

-

-

-

.024

CEQ After effects

-

22 (0-50)

23 (0-50)

19 (11-28)

-

-

-

.274

CEQ Amotivational

-

14 (0-34)

14 (0-34)

15 (7-21)

-

-

-

.621

CEQ Psychosis-like experiences

-

6 (0-16)

10 (0-16)

5 (4-9)

-

-

-

.025

Hours since last use

-

15 (13-168)

14 (13-48)

18 (13-168)

-

-

-

.083

Frequency (days/month)

-

27 (15-30)

29 (20-30)

26 (15-30)

-

-

-

.433

Quantity (cones/month)

-

338 (34-3150)

372 (138-3150)

195 (34-1080)

-

-

-

.523

Age of first use (years)

-

14.5 (10-19)

14.8 (10-16)

13.5 (11-19)

-

-

-

.859

Age started regular use (years)

-

16 (10-21)

15.5 (10-19)

16 (13.5-21.0)

-

-

-

.391

Duration of regular use (years)

-

9.4 (2.6-36.0)

6.1 (2.6-8.4)

23.2 (9.4-36.0)

-

-

-

.000

Duration of daily use (months)

-

60 (0.25-204.0)

30 (0.25-88.3)

72.0 (12.0-204.0)

-

-

-

.062

MWC (withdrawal) score

-

6.50 (1-33)

12.5 (2-33)

4.5 (1-11)

-

-

-

.008

Urinary cannabinoid metabolite
(THC- COOH) (ng/ml)

-

745 (108-9351)

828 (239-3658)

393 (108-9351)

-

-

-

.130

Cannabis Use

a.

Notes: Parametric tests performed (independent samples t-test). Significant p < .05 are noted by italics

Table 2.Mean (SD) P50 metrics for healthy nonuser controls, cannabis users (all), short-term and long-term user groups.

Control (n = 20)

Cannabis (All; n = 21)

Short-term users
(n=10)

Long-term users (n=11)

P50 S1 amplitude (μV)

4.55 (3.03)

3.51 (1.81)

3.87 (1.22)

3.18 (2.22)

P50 S2 amplitude (μV)

1.39 (1.10)

1.50 (1.04)

1.25 (0.70)

1.71 (1.28)

P50 ratio (S2/S1)

0.32 (0.24)

0.50 (0.40)

0.37 (0.29)

0.63 (0.45)

P50 difference score (S1-S2)

3.17 (2.41)

2.02 (1.73)

2.62 (1.43)

1.47 (1.85)

P50 metric

Figure(s)

Figure captions
Figure 1: ERP waveforms to the first (S1; left) and second (S2; right) click at Cz. Cannabis users are shown in grey and control participants in black.
Amplitude is shown in μV on the y-axis and time in milliseconds along the x-axis.
Figure 2: Scatter plots showing association between P50 metrics (after square root transformation) and duration of regular cannabis use in years (after
natural log transformation) in cannabis users. P50 ratio (transformed) shown on left and P50 difference score (transformed) shown on right.
Figure 3: ERP waveforms to the first (S1; left) and second (S2; right) click at Cz. Short- and long-term cannabis users are shown in the solid grey thin and
thick lines respectively and control participants in black. Amplitude is shown in μV on the y-axis and time in milliseconds along the x-axis.
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